Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma - PubMed (original) (raw)
Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma
Rita A Sakr et al. Appl Immunohistochem Mol Morphol. 2010 Jul.
Abstract
The PI3K/PTEN pathway plays a major role in carcinogenesis. Dysregulation of this pathway occurs frequently in breast cancer, and loss of PTEN expression is emerging as a potentially important mechanism of resistance to the widely used anti-HER2 therapy, trastuzumab. However, assays for loss of PTEN expression have suffered from lack of consistency. Here, we describe an automated and reliable protocol for PTEN protein expression by immunohistochemistry in formalin-fixed paraffin-embedded tissue that can be easily incorporated into clinical trials.
Figures
FIGURE 1
Cell lines: positive PTEN staining in MCF7 breast cell line (A) and negative staining in MDA-MB-468 (B). FFPE breast tissues: positive PTEN staining in ductal carcinoma in situ (C); negative PTEN staining in ductal carcinoma in situ (D); positive PTEN staining in invasive carcinoma (E); negative PTEN staining in invasive carcinoma (F) with normal ductal epithelium and stroma serving as positive internal control. FFPE indicates formalin-fixed paraffin-embedded.
FIGURE 2
Semi-quantitative scoring: (A) score 0 = staining undetectable in tumor cells but present in surrounding normal ductal epithelial and stromal cells; (B) score 1 = staining weaker than surrounding normal ductal epithelial and stromal cells; (C) score 2 = staining equal to that of surrounding normal ductal epithelial and stromal cells.
Similar articles
- Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.
Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B. Garg K, et al. Int J Gynecol Pathol. 2012 Jan;31(1):48-56. doi: 10.1097/PGP.0b013e3182230d00. Int J Gynecol Pathol. 2012. PMID: 22123723 Free PMC article. - A robust immunohistochemical assay for detecting PTEN expression in human tumors.
Sangale Z, Prass C, Carlson A, Tikishvili E, Degrado J, Lanchbury J, Stone S. Sangale Z, et al. Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):173-83. doi: 10.1097/PAI.0b013e3181f1da13. Appl Immunohistochem Mol Morphol. 2011. PMID: 20930614 - Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry.
Schläfli AM, Berezowska S, Adams O, Langer R, Tschan MP. Schläfli AM, et al. Eur J Histochem. 2015 May 5;59(2):2481. doi: 10.4081/ejh.2015.2481. Eur J Histochem. 2015. PMID: 26150155 Free PMC article. - Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y, Lu D, Lira ME, Xu Q, Du Y, Xiong J, Mao M, Chung HC, Zheng G. Zhu Y, et al. Exp Mol Pathol. 2016 Apr;100(2):287-93. doi: 10.1016/j.yexmp.2015.11.027. Epub 2015 Nov 25. Exp Mol Pathol. 2016. PMID: 26626802 - PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tekesin K, Emin Gunes M, Bayrak S, Akar E, Ozturk T, Altinay S, Tural D. Tekesin K, et al. J BUON. 2019 Sep-Oct;24(5):1920-1926. J BUON. 2019. PMID: 31786856
Cited by
- Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention.
Buckley N, Boyle D, McArt D, Irwin G, Harkin DP, Lioe T, McQuaid S, James JA, Maxwell P, Hamilton P, Mullan PB, Salto-Tellez M. Buckley N, et al. Oncotarget. 2015 Dec 22;6(41):43244-54. doi: 10.18632/oncotarget.6525. Oncotarget. 2015. PMID: 26657114 Free PMC article. - Genomic complexity and AKT dependence in serous ovarian cancer.
Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S, Janakiraman M, Olvera N, Stevens EV, She QB, Aghajanian C, King TA, Stanchina Ed, Spriggs DR, Heguy A, Taylor BS, Sander C, Rosen N, Levine DA, Solit DB. Hanrahan AJ, et al. Cancer Discov. 2012 Jan;2(1):56-67. doi: 10.1158/2159-8290.CD-11-0170. Cancer Discov. 2012. PMID: 22328975 Free PMC article. - The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.
Saigusa N, Hirai H, Tada Y, Kawakita D, Nakaguro M, Tsukahara K, Kano S, Ozawa H, Kondo T, Okami K, Togashi T, Sato Y, Urano M, Kajiwara M, Shimura T, Fushimi C, Shimizu A, Okamoto I, Okada T, Suzuki T, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Takahashi H, Ando M, Kohsaka S, Matsuki T, Nagao T. Saigusa N, et al. Front Oncol. 2022 Feb 3;11:779882. doi: 10.3389/fonc.2021.779882. eCollection 2021. Front Oncol. 2022. PMID: 35186711 Free PMC article. - HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
Gajria D, Chandarlapaty S. Gajria D, et al. Expert Rev Anticancer Ther. 2011 Feb;11(2):263-75. doi: 10.1586/era.10.226. Expert Rev Anticancer Ther. 2011. PMID: 21342044 Free PMC article. Review. - PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer.
Lopez G, Noale M, Corti C, Gaudioso G, Sajjadi E, Venetis K, Gambini D, Runza L, Costanza J, Pesenti C, Grossi F, Maggi S, Ferrero S, Bosari S, Fusco N. Lopez G, et al. Int J Mol Sci. 2020 Feb 21;21(4):1461. doi: 10.3390/ijms21041461. Int J Mol Sci. 2020. PMID: 32098071 Free PMC article. Clinical Trial.
References
- Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–1947. - PubMed
- Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–362. - PubMed
- Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol. 2004;15:171–176. - PubMed
- Rhei E, Kang L, Bogomolniy F, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 1997;57:3657–3659. - PubMed
- Garcia JM, Silva J, Pena C, et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer. 2004;41:117–124. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous